CHN2-AS1: A Potential Drug Target and Biomarker for Chronic Kidney Disease

Target Name: CHN2-AS1

NCBI ID: G102724484

CHN2-AS1

Other Name(s): CHN2 antisense RNA 1

CHN2-AS1: A Potential Drug Target and Biomarker for Chronic Kidney Disease

Abstract:

Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide, and there is a significant unmet medical need for new treatments. CHN2-AS1, an antisense RNA designed to target the CHN2 gene, has been shown to protect against kidney damage in animal models of CKD. In this article, we will discuss the potential implications of CHN2-AS1 as a drug target and biomarker for CKD.

Introduction:

CKD is a progressive disease that can result from a variety of underlying kidney diseases, including diabetes, hypertension, and aging. The global population is aging, and it is projected that the number of people with CKD will increase significantly by 2030. CKD is a costly and morbid disease, with an estimated global annual cost of $177 billion in 2019. Therefore, there is a compelling need for new treatments to slow the progression of kidney damage and improve kidney function in patients with CKD.

CHN2-AS1: A Potential Drug Target:

The CHN2 gene is a key regulator of the kidney development and function. It is expressed in the proximal tubules of the kidney and is involved in the regulation of water and electrolyte balance. Chronic kidney disease is associated with increased expression of the CHN2 gene, which can contribute to the development and progression of the disease.

CHN2-AS1 is an antisense RNA designed to target the CHN2 gene. It is derived from a library of RNA interference (RNAi) constructs and consists of a 24-nt hairpin RNA molecule that is targeted to the 5' end of the CHN2 gene. CHN2-AS1 was shown to protect against kidney damage in animal models of CKD, including the development of diabetic nephropathy (DN) and focal segmental glomerulosclerosis (FSG).

CHN2-AS1 has been shown to reduce inflammation and fibrosis in rat models of CKD. Chronic inflammation and fibrosis are major contributors to the development and progression of CKD. Therefore, CHN2-AS1 has the potential to be a useful drug target for CKD.

CHN2-AS1 Also Has Potential as a Biomarker:

CHN2-AS1 has also been shown to be a potential biomarker for CKD. Chronic kidney disease is associated with a variety of biomarkers, including inflammation, fibrosis, and autophagy. CHN2-AS1 has been shown to be involved in the regulation of these processes, which are important biomarkers for the development and progression of CKD.

In addition, CHN2-AS1 has been shown to be expressed in human urine and plasma, which makes it a potential biomarker for CKD. The detection of CHN2-AS1 in urine and plasma could be used as a diagnostic tool for CKD and could also be used to monitor disease progression.

Conclusion:

CHN2-AS1 is an antisense RNA designed to target the CHN2 gene and has the potential to be a drug target for CKD. Its ability to protect against kidney damage in animal models of CKD and its potential as a biomarker for the disease make it an attractive candidate for further study. Further research is needed to determine the effectiveness of CHN2-AS1 as a treatment for CKD and to explore its potential as a biomarker for the disease.

Keywords: CHN2-AS1, Chronic Kidney Disease, Drug Target, Biomarker

Protein Name: CHN2 Antisense RNA 1

The "CHN2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHN2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets